



Box Sec
IFW

PATENT
0641-0260P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Huang BING-REN et al. Conf.: 5245
Appl. No.: 10/791,860 ✓ Group: 1646
Filed: March 4, 2004 Examiner: UNKNOWN
For: REGULATOR OF APOPTOSIS AND CELL
PROLIFERATION

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE
OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

April 26, 2005

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449(s), attached hereto.

II. COPIES (check at least one box)

- a. ☒ A CD-Rom is attached which contains thereon copies of all references listed on the attached PTO-1449 Form, including U.S. patents.
- b. ☐ Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

a. ☒ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The patents, publications, or other information listed on the attached PTO 1449 are in the English language and therefore, do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☐ **ENGLISH LANGUAGE SEARCH REPORT**

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III) (A) (3).

d. ☐ **OTHER**

The following additional information is provided for the Examiner's consideration.

FEEs

IV. ☒ THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b):
(check one box)

- a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. *(This section is not to be used with RCE's.)*
- b. ☐ within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.
- c. ☐ concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
- d. ☒ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required.
In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

V. ☐ THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

- a. ☐ No statement; therefore, a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).
- or
- b. ☐ See the statement below. No fee is required.

VI. STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby states that

- a. ☐ each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or
- b. ☐ each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- c. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.
- d. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VII. PAYMENT OF FEES (check one box)


- ☐ A check in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p) is enclosed for the above-identified fee.
- ☐ Please charge Deposit Account No. 02-2448 in the amount required by 37 C.F.R. § 1.17(p) for the above-indicated fee. This paper is submitted in triplicate.
- ☒ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Gerald M. Murphy, Jr., #28,977

P.O. Box 749
Falls Church, VA 22040-0747
(703) 205-8000

GMM/las
0641-0260P

Attachment(s) : ☒ **PTO-1449**
☐ Documents
☐ Foreign Search Report
☐ Fee
✓ ☒ **Other: CD-Rom containing references listed on
PTO-1449 Form**

Form PTO-1449		ATTY. DOCKET NO. 0641-0260P			APPLICATION NO. 10/791,860			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)					APPLICANT Huang BING-REN et al.			
FILING DATE March 4, 2004					GROUP 1646			
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
	US 2002/0127228	A1	2002-09-12	Kawamura et al.				
	US 2002/0102710	A1	2002-08-01	Bandman et al.				
	US 2002/0192745	A1	2002-12-19	Lehar et al.				
	US 2003/0059791	A1	2003-03-27	Rokutan et al.				
	US 5,847,093	A	1998-12-08	Bandman et al.				
	US 6,307,021	B1	2001-10-23	Bandman et al.				
	US 6,570,002	B1	2003-05-27	Harwick et al.				
	US 6,743,619	B1	2004-06-01	Tang et al.				
FOREIGN PATENT DOCUMENTS								
Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
WO	02/16439	A2	2002-02-28	WIPO				
WO	99/60124	A2	1999-11-25	WIPO				
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)								
	GenBank Accession No. AF304429; B. Dong et al., "A protein involved in apoptosis of rat neuronal cell," Unpublished; submitted (10-SEP-2000) Biochemistry, Institute of Basic Medical Science, Chinese Academy of Medical Sciences.							
	GenBank Accession No. U47315; H. Bingren et al., "Isolation and identification of cDNA involved apoptosis induced by low-affinity neurotrophic factor receptor on R2 cell line," Unpublished (1996); Chinese Academy of Medical Sciences and Peking Union Medical College							
	GenBank Accession No. U47316; H. Bingren et al., "Isolation and identification of cDNA involved apoptosis induced by low-affinity neurotrophic factor receptor on R2 cell line," Unpublished (1996); Chinese Academy of Medical Sciences and Peking Union Medical College							
	GenBank Accession No. NM_016098; R. L. Strausberg et al., "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences," <i>Proc. Natl. Acad. Sci. USA</i> , 99(26), 16899-16903 (2002) and C. H. Lai et al., "Identification of novel human genes evolutionarily conserved in <i>Caenorhabditis elegans</i> by comparative proteomics," <i>Genome Res.</i> , 10(5) 703-713 (2000)							
	GenBank Accession No. NM_018819; The FANTOM Consortiu and the RIKEN Genome Exploration Research Group Phase I and II Team, "Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs," <i>Nature</i> , 420, 563-573 (2002) and Z. Trachtulec et al., "Synteny of orthologous genes conserved in mammals, snake, fly, nematode, and fission yeast," <i>Mamm. Genome</i> , 12(3), 227-231 (2001)							
	B.-R. Huang et al., <i>Neurochemistry International</i> 36 (2000) 55-65							
	M. Majdan et al., <i>The Journal of Cell Biology</i> , Vol. 155, No. 7, December 24, 2001, 1275-1285							
EXAMINER					DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

6m

GMM/las

Form PTO-1449		ATTY. DOCKET NO. 0641-0260P	APPLICATION NO. 10/791,860
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		APPLICANT Huang BING-REN et al.	
		FILING DATE March 4, 2004	GROUP 1646
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	T. Jover et al., <i>The Journal of Neuroscience</i> , March 15, 2002, 22(6):2115-2124		
	S. Rabizadeh et al., <i>Science</i> , Vol. 261(5119) 16 July 1993, pp. 345-348		
	X. Wang et al., <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 36, September 7, 2001, pp. 33812-33820		
	S. Irie et al., <i>FEBS Letters</i> , 460 (1999) 191-198		
	S. Casha et al., <i>Neuroscience</i> , Vol. 103, No. 1, pp. 203-218, 2001		
	E. Casademunt et al., <i>The EMBO Journal</i> , Vol. 18, No. 21, pp. 6050-6061, 1999		
	X. Ye et al., <i>The Journal of Biological Chemistry</i> , Vol. 274, No. 42, October 15, 1999, pp. 30202-30208		
	A. L. Hughes et al., <i>Journal of Neuroscience Research</i> , Vol. 63:10-19 (2001)		
	R. Lee et al., <i>Science</i> , Vol. 294, pp. 1945-1948, November 30, 2001		
	J. A. Park et al., <i>The Journal of Neuroscience</i> , December 15, 2000, 20(24):9096-9103		
	D. P. Martin et al., <i>The Journal of Cell Biology</i> , Vol. 106, March 1988, 829-844		
	M. Majdan et al., <i>The Journal of Neuroscience</i> , September 15, 1997, 17(18) 6988-6998		
	M. Yaar et al., <i>The Journal of Biological Chemistry</i> , Vol. 277, No. 10, March 8, 2002, pp. 7720-7725		
	G. Tagliatela et al., <i>Journal of Neurochemistry</i> , Vol. 66, No. 5, 1996, pp. 1826-1835		
	S. Rabizadeh et al., <i>Science</i> , Vol. 261, July 16, 1993, pp. 345-348		
	G. L. Barrett et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 6501-6505, July 1994		
	Y. Muragaki et al., <i>The Journal of Neuroscience</i> , January 15, 1997, 17(2):530-542		
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

GM

GMM/las

Form PTO-1449		ATTY. DOCKET NO. 0641-0260P	APPLICATION NO. 10/791,860
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		APPLICANT Huang BING-REN et al.	
		FILING DATE March 4, 2004	GROUP 1646
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	J. M. Frade et al., <i>Nature</i> , Vol. 383, September 12, 1996, pp. 166-168		
	P. Casaccia-Bonofil et al., <i>Nature</i> , Vol. 383, October 24, 1996, pp. 716-719		
	B. Pettmann et al., <i>Neuron</i> , Vol. 20, 633-647, April 1998		
	G. B. Stokin et al., <i>Science</i> , Vol. 307, February 25, 2005, pp. 1282-1288		
	A. D. Cash et al., <i>American Journal of Pathology</i> , Vol. 162, No. 5, May 2003, 1623-1627		
	M. T. Kimura et al., <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 20, May 18, 2001, pp. 17291-17300		
	C. M. Troy et al., <i>The Journal of Biological Chemistry</i> , Vol. 277, No. 37, September 13, 2002, pp. 34295-34302		
	A. W. Harrington et al., <i>The Journal of Neuroscience</i> , January 1, 2002, 22(1):156-166		
	G. Khursigara et al., <i>The Journal of Neuroscience</i> , August 15, 2001, 21(16):5854-5863		
	P. P. Roux et al., <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 25, June 22, 2001, pp. 23097-23104		
	V. A. Botchkarev et al., <i>The FASEB Journal</i> , Vol. 14, October 2000, pp. 1931-1942		
	S. S. Cheema et al., <i>Journal of Neuroscience Research</i> , 46:239-245 (1996)		
	A. H. Salehi et al., <i>The Journal of Biological Chemistry</i> , Vol. 277, No. 50, December 13, 2002, pp. 48043-48050		
	P. Villa et al., <i>Journal of Neurochemistry</i> , Vol. 62, No. 4, 1994, pp. 1468-1475		
	C. N. Svendsen et al., <i>The Journal of Neuroscience</i> , January 1994, 14(1):75-87		
	C. S. von Bartheld et al., <i>Neuron</i> , Vol. 12, 639-654, March 1994		
	J.-Y. Koh et al., <i>Science</i> , Vol. 268, 28 April 1995, pp. 573-575		
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

gm

GMM/las